Travere Therapeutics' Change in Receivables rose 5940.36% to $44.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $57.6 million, marking a year-over-year increase of 380.77%. This contributed to the annual value of $6.0 million for FY2024, which is 46.72% down from last year.
Latest data reveals that Travere Therapeutics reported Change in Receivables of $44.2 million as of Q3 2025, which was up 931.18% from $4.3 million recorded in Q2 2025.
In the past 5 years, Travere Therapeutics' Change in Receivables registered a high of $44.2 million during Q3 2025, and its lowest value of -$5.7 million during Q3 2022.
For the 3-year period, Travere Therapeutics' Change in Receivables averaged around $6.6 million, with its median value being $2.0 million (2024).
Per our database at Business Quant, Travere Therapeutics' Change in Receivables plummeted by 4,773.77% in 2021 and then skyrocketed by 5,940.36% in 2025.
Travere Therapeutics' Change in Receivables (Quarterly) stood at $1.7 million in 2021, then soared by 248.26% to $6.0 million in 2022, then skyrocketed by 32.73% to $8.0 million in 2023, then crashed by 75.10% to $2.0 million in 2024, then soared by 5,940.36% to $44.2 million in 2025.
Its Change in Receivables was $44.2 million in Q3 2025, compared to $4.3 million in Q2 2025 and $7.2 million in Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value